Not Yet RecruitingNot Applicable

The Effect of Remotely Delivered Pilates on Physical , and Psychological Outcomes in Individuals With Multiple Sclerosis

50 participantsStarted 2026-06-01

Plain-language summary

Objectives Objective 1: To determine the effects of a 16-week remotely delivered Pilates intervention on walking endurance, walking speed, balance, fatigue, and pain compared to a waitlist control group in individuals with MS. Objective 2: To examine the impact of a 16-week remotely delivered Pilates intervention on depression \& anxiety, cognitive function, and QOL compared to a waitlist control group in individuals with MS. Aim Aim 1: To assess whether the 16-week remotely delivered Pilates intervention significantly improves walking endurance, walking speed, balance, fatigue, and pain compared to a waitlist control group in individuals with MS Aim 2: To investigate whether the 16-week remotely delivered Pilates intervention significantly improves depression \& anxiety, cognitive function, and QOL compared to a waitlist control group in individuals with MS. Hypothesis Hypothesis 1: The 16-week remotely delivered Pilates intervention will significantly improve walking endurance, walking speed, balance, fatigue, and pain compared to a waitlist control group in individuals with MS. Hypothesis 2: Participants receiving the 16-week remotely delivered Pilates intervention will demonstrate significantly greater improvements in depression \& anxiety, cognitive function, and QOL compared to a waitlist control group in individuals with MS.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age 18 years or older * Self-reported diagnosis of multiple sclerosis by a neurologist * Relapse-free for the past 30 days before screening * Able to speak and read English as the primary language * Access to the internet and e-mail, * Ability to use Zoom, and willingness to complete testing sessions and questionnaires * Ambulatory without an assistive device (for example, cane) * Low to moderate disability, defined as a score of 0-4 on the Patient-Determined Disease Steps (PDDS) * Insufficiently active, defined as a score \< 14 on the Godin Leisure-Time Exercise Questionnaire-Health Contribution Score (GLTEQ-HCS) * Adequate visual ability and literacy to read materials printed in 14-point font * Currently treated with a disease-modifying therapy Exclusion Criteria: * Pregnant * Elevated risk for strenuous or maximal exercise, defined as more than one "Yes" response on the Physical Activity Readiness Questionnaire (PAR-Q) during screening

What they're measuring

Change from baseline in walking endurance (Six-Minute Walk Test distance)

Timeframe: Baseline and 16 weeks (end of treatment)

Change from baseline in walking speed (Timed 25-Foot Walk)

Timeframe: Baseline and 16 weeks (end of treatment)

Change from baseline in balance (Berg Balance Scale)

Timeframe: Baseline and 16 weeks (end of treatment)

Change from baseline in fatigue (Fatigue Severity Scale)

Timeframe: Baseline and 16 weeks (end of treatment)

Change from baseline in pain (Short-form McGill Pain Questionnaire)

Timeframe: Baseline and 16 weeks (end of treatment)

Trial details

NCT IDNCT07504120

SponsorUniversity of Illinois at Chicago

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-11-01

View on ClinicalTrials.gov More Multiple Sclerosis trials

Plain-language summary

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

Change from baseline in walking endurance (Six-Minute Walk Test distance)

Timeframe: Baseline and 16 weeks (end of treatment)

Change from baseline in walking speed (Timed 25-Foot Walk)

Timeframe: Baseline and 16 weeks (end of treatment)

Change from baseline in balance (Berg Balance Scale)

Timeframe: Baseline and 16 weeks (end of treatment)

Change from baseline in fatigue (Fatigue Severity Scale)

Timeframe: Baseline and 16 weeks (end of treatment)

Change from baseline in pain (Short-form McGill Pain Questionnaire)

Timeframe: Baseline and 16 weeks (end of treatment)